U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

  1. Home
  2. Drugs
  3. News & Events for Human Drugs
  4. CDER SBIA Webinar: Updates on FDA’s Drug-Drug Interaction Final Guidances - 04/24/2020
  1. News & Events for Human Drugs

Webcast | Mixed

Event Title
CDER SBIA Webinar: Updates on FDA’s Drug-Drug Interaction Final Guidances
April 24, 2020


Date:
April 24, 2020
Time:
1:30 PM - 3:00 PM ET

Follow us on LinkedIn

 

View Slides

ABOUT

This webinar will discuss two FDA final guidances that provide a systemic approach to the evaluate the drug-drug interaction (DDI) potential of investigational drugs and describe how the approach can be implemented. The two final guidances are:

LEARNING OBJECTIVES

At the end of this webinar, participants should be able to:

  • Understand the important role of in vitro DDI evaluations and how they inform clinical DDI assessment.
  • Describe the need for, timing of, and multiple design features of clinical DDI studies.
  • Interpret in vitro and clinical DDI study findings and translation of those findings into DDI management strategies that health care providers communicate to patients.

INTENDED AUDIENCE

  • Scientists in pharmaceutical companies and contract research organizations working on drug metabolism, pharmacokinetics, and clinical pharmacology
  • Regulatory reviewers and policy makers working in those areas
  • Academic researchers in those fields
  • Pharmacists
  • Healthcare providers prescribing drugs to patients

FDA SPEAKERS

Dr. Kellie Reynolds, Pharm. D.
Director
Division of Infectious Disease Pharmacology | Office of Clinical Pharmacology | CDER | FDA

Dr. Xinning Yang, Ph.D.
Policy Lead
Guidance & Policy Team | Office of Clinical Pharmacology | CDER | FDA

RESOURCES

  1. FDA guidance for industry: In Vitro Drug Interaction Studies - Cytochrome P450 Enzyme- and Transporter-Mediated Drug Interactions,
  2. FDA guidance for industry: Clinical Drug Interaction Studies - Cytochrome P450 Enzyme- and Transporter-Mediated Drug Interactions,
Back to Top